イスラエル - ヘブライ語 - Ministry of Health

boehringer ingelheim israel ltd. - nevirapine anhydrous (as hemihydrate) - תרחיף - nevirapine anhydrous (as hemihydrate) 50 mg / 5 ml - nevirapine - nevirapine - for use in combination with other antiretroviral agents for the treatment of hiv-1 infection.

イスラエル - ヘブライ語 - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

イスラエル - ヘブライ語 - Ministry of Health

j-c health care ltd - emtricitabine; rilpivirine as hydrochloride; tenofovir disoproxil as fumarate - טבליות מצופות פילם - tenofovir disoproxil as fumarate 245 mg; rilpivirine as hydrochloride 25 mg; emtricitabine 200 mg - rilpivirine - rilpivirine - eviplera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of hiv-1 infection in antiretroviral treatment-naive adults. this indication is based on week 48 safety and efficacy analyses from 2 randomized, double-blind, active controlled, phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz . the following points should be considered when initiating therapy with eviplera: -more rilpivirine-treated subjects with hiv-1 rna greater than 100,000 copies/ml at the start of therapy experienced virologic failure compared to subjects with hiv-1 rna less than 100,000 copies/ml at the start of therapy. -the observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the nnrti class compared to efavirenz . -more subjects treated with rilpivirine developed lamivudine/emtricitabine associated resistance compared to efavirenz. -eviplera is not recomme

イスラエル - ヘブライ語 - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

イスラエル - ヘブライ語 - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

イスラエル - ヘブライ語 - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

イスラエル - ヘブライ語 - Ministry of Health

dexcel ltd, israel - ciclosporin - קפסולות - ciclosporin 100 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

イスラエル - ヘブライ語 - Ministry of Health

dexcel ltd, israel - ciclosporin - קפסולות - ciclosporin 25 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney liver heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejection in patients previously treated with other immuno-suppressive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that did not respond to other treatment. atopic dermatitis in adults only up to 8 weeks for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis: severe cases in which standard treatments are ineffective or inappropriate. nephrotic syndrom type mcd (minimal change disease) in cases where conventional therapy has failed.

イスラエル - ヘブライ語 - Ministry of Health

dexcel ltd, israel - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejections in patients previously treated with other immunosuppresive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that does not respond to other treatment . atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis, severe cases when standard treatment is ineffective or inappropriate. nephrotic syndrome type mcd (minimal change disease) in cases where conventional therapy has failed.

イスラエル - ヘブライ語 - Ministry of Health

eli lilly israel ltd, israel - duloxetine as hydrochloride - קפסולות - duloxetine as hydrochloride 20 mg - duloxetine - duloxetine - yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (sui).